SAN FRANCISCO, Sept. 18 /PRNewswire/ — DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that CEO David Cory will deliver a corporate presentation at the upcoming Biotechnology Industry Organization (BIO) Mid-America Venture Forum in Milwaukee, Wisconsin. The DiObex presentation will take place on Wednesday, September 26th at 1:30 p.m. at the Hyatt Regency Hotel in Room A.
About DiObex
DiObex, Inc. is a San Francisco-based biotechnology company founded to develop novel products for the treatment of metabolic diseases. DiObex has two product candidates in Phase 2 clinical development. DIO-901 (very low dose glucagon) is in development as an extended release subcutaneous formulation for reducing or preventing insulin-induced hypoglycemia in type 1 diabetes mellitus. DIO-901 has received Fast Track status from the Food and Drug Administration. DIO-902 (levdexketoconazole) is a novel cortisol synthesis inhibitor in development for type 2 diabetes mellitus. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type 2 diabetes mellitus and cardiovascular disease. For more information, visit http://www.diobex.com/.
First Call Analyst:
FCMN Contact:
Source: DiObex, Inc.
CONTACT: Erika Lum of DiObex, +1-415-551-4112, elum@diobex.com
Web site: http://www.diobex.com/
